Elanco Animal Health (NYSE:ELAN – Free Report) had its target price trimmed by Barclays from $20.00 to $19.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Elanco has struck an agreement to distribute a vaccine that may protect cattle for up to 12 months against bird flu ...

Full Year 2024 Results Key Financial Results Revenue: US$4.44b (flat on FY ...

Animal health company Elanco (NYSE:ELAN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales ...

Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $13 from $14 and keeps an Equal Weight rating on the shares. Q4 EPS of 14c ...

Zoetis also has an H5N1 vaccine, for which it received a conditional license in 2016 and a contract award for the USDA’s ...

Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid ...

Shares of Mosaic Co. slipped 4.66% to $23.92 Friday, on what proved to be an all-around positive trading session for the ...

Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.

Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.

Elanco Animal Health (NYSE:ELAN) stock falls as the company reports mixed Q4 2024 results, and sets 2025 outlook below consensus due to forex headwinds. Read more here.